Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials


Safety and Feasibility of Psilocybin in Methamphetamine Use Disorder in a Community-Based Sample


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT05322954

Organisation Name: University of Wisconsin, Madison

Overal Status: Not yet recruiting

Start Date: July 2022

Last Update: May 6, 2022

Lead Sponsor: University of Wisconsin, Madison

Brief Summary: The purpose of this research study is to investigate the safety and feasibility of two (2) oral doses of psilocybin when combined with behavioral support for methamphetamine use disorder (MUD). Participants have a diagnosis of mild or moderate methamphetamine use disorder (MUD). Participants can expect to be actively engaged in the study for up to 26 weeks.

Conditions:
  • Methamphetamine Use Disorder
  • Substance-Related Disorders
  • Chemically-Induced Disorders
  • Substance Use Disorders
  • Stimulant-Use Disorder


Total execution time in seconds: 0.25041890144348